American Journal of Cardiovascular Drugs

, Volume 17, Issue 6, pp 497–498 | Cite as

Authors’ Reply to Urtasun et al.: “Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs”

  • Dixon Thomas
  • Seeba Zachariah
  • Kishore Gnana Sam Sundararaj
  • Matthew Van Cuyk
  • Jason C. Cooper
Letter to the Editor
  • 63 Downloads

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this reply.

Conflict of interest

Dixon Thomas, Seeba Zachariah, Kishore Gnana Sam Sundararaj, Matthew Van Cuyk, and Jason C. Cooper have no potential conflicts of interest that might be relevant to this reply.

References

  1. 1.
    Urtasun MA, Prozzi GR, Marín GH, Buschiazzo HO, Cañás M, Dorati CM, Mordujovich P. Comment on: “Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs”. Am J Cardiovasc Drugs. 2017. doi: 10.1007/s40256-017-0235-2.
  2. 2.
    Thomas D, Ali Z, Zachariah S, et al. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Am J Cardiovasc Drugs. Epub 28 Mar 2017. doi: 10.1007/s40256-017-0223-6.
  3. 3.
    Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29.CrossRefPubMedGoogle Scholar
  4. 4.
    FitzGerald GA. Imprecision: limitations to interpretation of a large randomized clinical trial. Circulation. 2017;135(2):113–5. doi: 10.1161/CIRCULATIONAHA.116.026324.CrossRefPubMedGoogle Scholar
  5. 5.
    Wendling P. PRECISION: Celecoxib Similar to Ibuprofen, Naproxen for CV Risk. Medscape. 2016. http://www.medscape.com/viewarticle/871835 Accessed 5 May 2017.
  6. 6.
    Grosser T. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2017;376(14):1389. doi: 10.1056/NEJMc1702534.CrossRefPubMedGoogle Scholar
  7. 7.
    Nissen SE. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2017;376(14):1390. doi: 10.1056/NEJMc1702534.CrossRefPubMedGoogle Scholar
  8. 8.
    Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79. doi: 10.1016/S0140-6736(13)60900-9.CrossRefGoogle Scholar
  9. 9.
    Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. Epub 11 April 2017. doi: 10.1016/S0140-6736(17)30981-9.
  10. 10.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42(1):27–38. doi: 10.1111/jcpt.12484.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Dixon Thomas
    • 1
  • Seeba Zachariah
    • 1
  • Kishore Gnana Sam Sundararaj
    • 1
  • Matthew Van Cuyk
    • 2
  • Jason C. Cooper
    • 2
  1. 1.College of PharmacyGulf Medical UniversityAjmanUnited Arab Emirates
  2. 2.Medical University of South Carolina Drug Information CenterCharlestonUSA

Personalised recommendations